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Data from Basic Health Research shows the prevalence of heart failure in Indonesia is between 
0.1% to 0.3% of the entire Indonesian population. This number is predicted to increase from year to 
year. Heart failure is a complex syndrome that can cause abnormalities in the structure and function of 
the heart. Based on the ejection fraction values, there are three types of heart failure, namely HFrEF 
(EF: < 40%), HFmrEF (EF: 40-49%), and HFpEF (EF: ≥ 50%). Considering that the type of heart 
failure requiring treatment according to ESC guidelines is only HFrEF, however, this study would also 
evaluate the effect of physician prescribing patterns on the morbidity of HFmrEF. The recommendations 
from ESC guidelines to the treatment of HFrEF that can reduce morbidity and mortality are three 
medication combinations, namely ACE inhibitors/angiotensin receptor blockers, beta-blockers, and 
aldosterone antagonists. Therefore, this study aims to determine the effect of the suitability of physician 
prescribing patterns according to ESC guidelines on improving the morbidity of heart failure patients in 
HFrEF and HFmrEF type. Improvements in morbidity can be seen from the quality of life score and 
frequency of hospitalization by using questionnaires. The study was conducted in the cardiology 
outpatient clinic of Dr. Saiful Anwar General Hospital and Islamic Hospital of Aisyiyah in April-May 
2019. Subjects who participated in the study were 57 patients. The One-way ANOVA test results 
showed no significant difference between physician prescribing patterns of quality of life scores on 
HFrEF (p = 0.944) while the Kruskal Wallis test for the same parameters on HFmrEF also showed 
insignificant results (p = 0.210). The Kruskal Wallis test results showed no significant difference 
between the patterns of physician prescribing to the frequency of hospitalization in both HFrEF and 
HFmrEF (p = 0.260; p = 0.428). The results showed that physician prescribing patterns in accordance 
with ESC guidelines resulted in the best quality of life scores on HFrEF. The lowest frequency of 
hospitalization was also shown in HFrEF patients who received treatment according to ESC guidelines.  
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As many as 17.9 million people (31%) of 58 million deaths in the world are caused by 
cardiovascular disease (WHO, 2020). Indonesia occupies the second-highest rank in Southeast Asia 
with a total of 371 thousand cardiovascular patients (WHO, 2007). Heart failure can be caused by an 
abnormal structure and function of heart condition that causes a decrease in heart-pumping capacity 
thereby reducing ventricular filling and contraction of the myocardium. In the case of myocardial 
infarction, chronic hypertension, and cardiomyopathy, the heart undergoes cell remodeling through a 
variety of complex biochemical mechanisms (Mcmurray et al., 2012). 
The remodeling process in the initial phase can improve the necrosis area and the formation of 
scar tissue so that there is no expansion of infarction. However, the amount of remodeling is 
proportional to the size of the infarction. After infarction occurs, the area of injury soon expands, 
followed by regional dilation and thinning infarction zone. This situation causes changes in ventricular 
mass, composition, and volume that can affect the heart function (Kehat and Molkentin, 2010).  
The results of the meta-analysis showed that cardiac medications that can cause a decrease in 
mortality and morbidity are a combination of ACE inhibitors, beta-blockers, and aldosterone antagonists 
(56%); monotherapy ACE inhibitor (16%); and monotherapy angiotensin receptor blockers (12%) 
(Burnett et al., 2017). This finding refers to the European Society of Cardiology (ESC) guidelines that 
the use of a combination of the three medications, that are ACE inhibitors, beta-blockers, and 
aldosterone antagonists, can increase the highest survival. Therefore, a combination of the three 
medications is recommended for patients with HFrEF (Heart Failure with reduced Ejection Fraction) 
except those who are intolerant of these medications (Ponikowski et al., 2016). 
The therapeutic error can be influenced by several factors, namely errors in medications selection, 
dosage, method of use, and illegible writing (Oshikoya et al., 2009). According to data on prescribing 
patterns for heart failure medications in Asia, the most common pattern of using heart failure 
medications in Indonesia is ACE inhibitors/angiotensin receptor blockers (87%), and the least is beta-
blockers (61%) (Teng et al., 2018). Therefore, a current alignment of patient therapy to the guidance is 
crucial for the management of heart failure patients. 
The basic goals of heart failure therapy include improving symptoms, increasing functional 
capacity, improving quality of life, decreasing hospitalization frequency, and decreasing mortality rates 
(Berliner and Bauersachs, 2017). Consequently, this study focuses on analyzing the differences in the 
morbidity of patients with HFrEF and HFmrEF (Heart Failure with mid-ranged Ejection Fraction) on 
the suitability of physician prescribing patterns according to ESC guidelines. The parameters used in 
this study to assess the improvement in morbidity are increasing the quality of life scores and decreasing 
the frequency of hospitalization. 
  
MATERIALS AND METHODS  
The design of this study was an observational analytic with a cross-sectional study approach. The 
study used medical records and modified MLHF (Minnesota Living with Heart Failure) questionnaires. 
This study compared the improvement in the morbidity of patients who received appropriate and 
inappropriate prescribing patterns that refer to ESC guidelines. Based on the calculation of the sample 
size formula, it is known that the minimum sample size in this study was 51 patients. To obtain the 
sample size, a two-month study was conducted, from April to May 2019. 
The study inclusion criteria were adult patients aged > 25 years with a diagnosis of heart failure, 
have received heart failure medications and have taken routine medications for at least the last three 
months, had an ejection fraction value < 50%, and were willing to participate in the study. The study 
was conducted at Dr. Saiful Anwar General Hospital and Islamic Hospital of Aisyiyah in Malang. This 
research methodology has obtained ethical clearance from the Health Research Ethics Commission    
Dr. Saiful Anwar General Hospital Malang through decree number 400/048/K.3/302/2019.  
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The morbidity assessment on the presence or absence of significant differences in the quality of 
life scores between medication groups in HFrEF patients was using the One-way ANOVA, while in 
HFmrEF patients was using with the Kruskal Wallis. Morbidity assessment on the presence or absence 
of significant differences in the frequency of repeated hospitalizations within the last six months 
between medication groups in HFrEF and HFmrEF patients was using the Kruskal Wallis. The p-value 
was significant if < 0.05 at 95% confidence interval. 
 
RESULT AND DISCUSSION  
This study obtained 57 HFrEF and HFmrEF patients that met the inclusion and exclusion criteria. 
Based on the ejection fraction value, there were three types of heart failure, namely HFrEF (Heart 
Failure with reduced Ejection Fraction) (EF: < 40%), HFmrEF (Heart Failure with mid-ranged Ejection 
Fraction) (EF: 40-49%), and HFpEF (Heart Failure with preserved Ejection Fraction) (EF: ≥ 50%) 
(Ponikowski et al., 2016). Patient characteristics were based on age group, gender, and comorbid 
diseases as seen in Table 1. The elderly group (54.4%) is the age group that experience heart failure 
more because the prevalence of heart failure increases with age which is around 0.5% at the age of 20-
39 years, and the prevalence will continue to increase to more than 10% at the age of 80 years and over. 
This is due to aging factors in the structure and function of the heart including increased arterial and 
heart muscle stiffness, decreased relaxation of the diastolic heart muscle, and an increase in left 
ventricular mass (Upadhya and Kitzman, 2017). Based on gender, this study showed that patients who 
had more heart failure were men (77.2%) than women (22.8%). This refers to the latest results from the 
Framingham Heart Study over the past 40 years that the cases of heart failure in women have decreased 
by about one third while in men there is no change in the prevalence of heart failure (Parker et al., 
2008). The results of the Framingham Heart Study show that the etiology of heart failure can be sorted 
hierarchically into Coronary Heart Disease (CHD), valvular heart disease, hypertension, and other 
etiologies/unknown (Lee et al., 2009). The percentage hierarchy of comorbidities in this study ranging 
from the largest to the lowest were CHD (35.0%), unknown (26.3%), Diabetes Mellitus (DM) + CHD 
(19.3%), hypertension + CHD (8.8%), DM (5.3%), hypertension + DM (1.8%), hypertension + DM + 
CHD (1.8%), and hypertension (1.7%).  
 





















Characteristics  Number of Patients  (%) 
Age  
26-55 years old   26 (45.6) 
> 55 years old    31 (54.4) 
Total 57 (100.0) 
Gender   
Male  44 (77.2) 
Female  13 (22.8) 
Total  57 (100.0)  
Comorbid Diseases   
Coronary Heart Disease (CHD) 20 (35.0)  
Unknown  15 (26.3)  
DM + CHD   11 (19.3)  
Hypertension + CHD  5 (8.8)  
Diabetes Mellitus (DM)   3 (5.3)  
Hypertension  1 (1.8)  
Hypertension + DM 1 (1.8)  
Hypertension + DM + CHD 1 (1.8)  
Total 57 (100.0)  
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Based on the results of the study (Table 2), the most prescribed medication for heart failure by 
physician for HFrEF and HFmrEF patients was a combination of three medications, i.e. ACE 
inhibitors/angiotensin receptor blockers, beta-blockers (bisoprolol), and aldosterone antagonists 
(spironolactone), which was 25 patients (43.9%). This was in accordance with ESC guidelines for the 
treatment of HFrEF patients but the therapy management for HFmrEF patients does not have to use the 
combination of these three medications (Ponikowski et al., 2016). Therefore, the definition of therapy 
according to ESC guidelines was that if HFrEF patients get a combination of the three medications 
(58.1%) and the therapy was said to be inappropriate if the physician prescribes it outside of the 
combination of the three medications, i.e. monotherapy ACE-I/ARB (3.2%), ACE-I/ARB + Bisoprolol 
(19.4%), or ACE-I/ARB + Spironolactone (19.4%). Meanwhile, all HFmrEF patients have received 
appropriate treatment because according to ESC guidelines there was no specific treatment that shows a 
decrease in morbidity or mortality in patients with HFpEF or HFmrEF. However, these HFpEF or 
HFmrEF patients were mostly among the elderly, very symptomatic, and often have a poor quality of 
life, so the important goal of therapy for this group of patients was to reduce the symptoms and improve 
health (Ponikowski et al., 2016).  
 
Table 2. Physician prescribing patterns for HFrEF and HFmrEF patients 
 
Notes: 
ACE-I = Angiotensin Converting Enzyme Inhibitor; ARB = Angiotensin Receptor Blocker; Biso = Bisoprolol; 
Spiro = Spironolactone 
 
The success of heart failure treatment in this study was measured through two parameters, namely 
the assessment of the patients’ quality of life and the frequency of repeated hospitalizations in the 
hospital in the past six months. Quality of life related to Health-related Quality of Life (HQoL) includes 
functional limitations that are physical, mental, and spiritual. HQoL can be used as an integrative 
measure that brings together mortality and morbidity (Syahidah, 2017). Symptoms of heart failure such 
as shortness of breath and fatigue can be related to patients’ physical activity limitations and 
physiological pressure which can worsen their health related to HQoL. Therefore, HQoL was used as a 
predictor of morbidity for heart failure patients which can be in a form of measurement of the results of 
intervention evaluation and predictions of hospitalization events and mortality (Tangsatitkiat and 
Sakthong, 2010). The quality of life of heart failure patients can be affected by several factors, such as 
age, ejection fraction, medications use, patient compliance, and economic level (Yaghoubi et al., 2012).  
Quality of life contains two components, the subjective component or people's perception and the 
objective component. In this study, the subjective component was used to assess the quality of life of 
heart failure patients through a set of questions or questionnaires. The answers to these questions were 
then changed to values or scales so that they can be measured objectively (Brink et al., 2009). In 
general, HQoL can be measured by two approaches, i.e. general and specific instruments (Rascati, 
2014). Specific instruments for heart disease include Minnesota Living with Heart Failure Questionnaire 
Suitability of  
HFrEF Therapy 
Number of Patients 
(%) 




Appropriate   18 (58.1)  Appropriate  26 (100.0)  
ACE-I/ARB + Biso + 
Spiro  
18 (58.1)  
ACE-I/ARB + Biso  
ACE-I/ARB + Biso + Spiro  
ACE-I/ARB + Spiro  
ACE-I/ARB single  
Biso single  
Biso + Spiro  
12 (46.2)  
7 (26.9)  
4 (15.4)  
1 (3.8)  
1 (3.8)  
1 (3.8)  
Inappropriate 13 (41.9)  
ACE-I/ARB + Biso  
ACE-I/ARB + Spiro  
ACE-I/ARB single  
6 (19.4)  
6 (19.4)  
1 (3.2)  
Total 31 (100.0) Total  26 (100.0)  
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(MLHFQ), Chronic Heart failure Questionnaire (CHQ), and Kansas City Cardiomyopathy 
Questionnaire (KCCQ). MLHFQ is the most widely used questionnaire as a disease-specific instrument 
for assessing the clinical condition of heart failure patients and has been used comprehensively to assess 
the perception of the effects of heart failure and its treatment on the daily lives of patients (Tangsatitkiat 
and Sakthong, 2010). This study used a modified MLHFQ questionnaire instrument so that it can assess 
the quality of life of HFrEF and HFmrEF patients. Interpretations of quality of life scores in this study 
were good quality of life (score ≤ 19), moderate quality of life (score 20-66), and poor quality of life 
(score ≥ 67).   
Validity and reliability test were conducted before the MLHFQ questionnaire was used to assess 
the HQoL of research subjects. The tests were carried out on five patients because the large sample 
requirements for the validity and reliability test is 10% of the total sample. The distribution of the r table 
with a significance value of 5% for five patients was 0.878. Therefore, Pearson correlation values on 
each question item that has a value > 0.878 can be declared valid and can be continued with the 
reliability test. In this study, from a total of 21 question items, it was found that only 17 items had a 
Pearson correlation value  > 0.878 (valid). Furthermore, a reliability test of the 17 question items was 
conducted. The research questionnaire was declared reliable because the value of Cronbach's alpha > 
alpha coefficient 0.6 was 0.987.  
The morbidity parameter consisted of quality of life scores and frequency of hospitalization. 
Hypothesis testing conducted was a comparative analysis to find out the comparison in the difference 
between physician prescribing patterns to the quality of life scores of patients with HFrEF and HFmrEF 
(p = 0.944; p = 0.210) and the frequency of repeated hospitalization of HFrEF and HFmrEF patients (p 
= 0.260; p = 0.428) at heart failure patients. The data can be seen in Table 3. Significance value for each 
parameter obtained was > 0.05 which means there was no statistically significant difference due to the 
disproportionate sample size between medication groups. The small sample size between the medication 
groups had caused no statistically apparent difference in morbidity parameters. However, the overall 
total sample obtained, as many as 57 patients, had met the minimum sample size requirements in this 
study.  However, the results showed that the use of prescription medications according to ESC 
guidelines (combination of 3 drugs) had the best assessment of morbidity conditions, i.e. the highest 
level of quality of life (score 25.81 included in the category of moderate quality of life) and the lowest 
frequency of hospitalization (score 1.00) in HFrEF patients. This was because HFrEF patients were 
known to benefit from a reduction in the morbidity rate from the use of the latest ESC guidance 
algorithm (Ponikowski et al., 2016). ACE (angiotensin-converting enzyme) inhibitors, angiotensin 
receptor blockers, and aldosterone antagonists act on the inhibition of the Renin-Angiotensin-
Aldosterone system that can overcome excessive activation in patients with heart failure (Martin et al., 
2018). Decreased sympathetic activity and decreased aldosterone and vasopressin can cause a decrease 
in arterial and venous pressure which can reduce preload and afterload. This can affect the increase in 
stroke volume and improve the ejection fraction. In addition, these medications also work as anti-
remodeling by inhibiting myocardial hypertrophy and apoptosis in cardiomyocytes due to decreased 
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Table 3. The morbidity parameters of HFrEF and HFmrEF patients according to  
the therapy group 
 
Notes:  
N/A: not available 
a
: The hypothesis test used is One-way ANOVA  
b
: The hypothesis test used is Kruskal Wallis  
p-value is statistically significant if < 0.05 at the 95% confidence interval  
ACE-I = Angiotensin Converting Enzyme Inhibitor; ARB = Angiotensin Receptor Blocker; Biso = Bisoprolol; 
Spiro = Spironolactone 
 
In HFmrEF patients, they have the same lowest frequency of hospitalization for both the 
combination of three medications (score 1.00) and the combination of ACE inhibitors/angiotensin 
receptor inhibitors + spironolactone (score 1.00). The highest level of quality of life was in patients who 
get monotherapy ACE inhibitors/angiotensin receptor blockers (score 14.00 included in the category of 
good quality of life). According to the latest ESC guideline therapy algorithm, there was no specific 
treatment that has been proven to show a decrease in morbidity in HFmrEF patients, so the treatments 
chosen are those that relieve the symptoms felt by the patient (Ponikowski et al., 2016).  
The frequency of repeated hospitalizations in HFrEF and HFmrEF patients that obtained a 
combination of three drugs according to the ESC guidelines in this study was quite good because 
patients only experienced once repeated hospitalization in the last six months. This shows that the 
patient did not experience a recurrence of episodes of heart failure (Majid, 2010). Based on Ogbemudia 
and Asekhame (2016), the highest rate of repeat admission was at the age > 65 years, which was about 
more than 50% of patients were retreated within six months after the hospital discharge (Ogbemudia and 
Asekhame, 2016). However, this did not occur in patients in this study whose majority were > 55 years 
old. This can be caused by several factors including the patients obtained good health education about 
how to take care for themselves at home, the patients used medications appropriately, there was good 
communication from health care providers to patients, and there was a good follow-up planning after 










Quality of Life Mean Scores   








Monotherapy ACE-I/ARB  28.00 1 14.00 1 
Biso + Spiro 0 0 48.00 1 
ACE-I/ARB + Biso 29.00 7 30.10 11 
ACE-I/ARB + Spiro 29.83 6 33.00 4 
ACE-I/ARB + Biso + Spiro 25.81 16 24.00 9 
Total  30   27  
Frequency of Repeated Hospitalizations   
Monotherapy Biso     0 0 
0.260
b





Monotherapy ACE-I/ARB  N/A 1 N/A 1 
Biso + Spiro 0 0 N/A 1 
ACE-I/ARB + Biso 1.75 7 1.67 11 
ACE-I/ARB + Spiro 1.60 6 1.00 4 
ACE-I/ARB + Biso + Spiro 1.00 16 1.00 9 
Total  30   27  
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 Based on the results of the study, it was found that the use of prescribing patterns according to 
ESC guidelines, that is a combination of three medications (ACE inhibitors/angiotensin receptor 
blockers, bisoprolol, and spironolactone), is the most commonly used for HFrEF and HFmrEF patients. 
In addition, HFrEF patients who have the highest level of quality of life and experience the lowest 
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